These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12747755)

  • 1. Urine antibody against human cancer antigen NY-ESO-1.
    Jäger D; Stockert E; Karbach J; Herrlinger K; Atmaca A; Arand M; Chen YT; Gnjatic S; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2002 Aug; 2():10. PubMed ID: 12747755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
    Gnjatic S; Atanackovic D; Jäger E; Matsuo M; Selvakumar A; Altorki NK; Maki RG; Dupont B; Ritter G; Chen YT; Knuth A; Old LJ
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8862-7. PubMed ID: 12853579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.
    Ayyoub M; Souleimanian NE; Godefroy E; Scotto L; Hesdorffer CS; Old LJ; Valmori D
    Clin Immunol; 2006; 118(2-3):188-94. PubMed ID: 16368270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
    Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
    Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
    Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
    Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.
    Valmori D; Souleimanian NE; Hesdorffer CS; Ritter G; Old LJ; Ayyoub M
    Clin Immunol; 2005 Oct; 117(1):24-30. PubMed ID: 15994128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
    Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
    Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
    Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
    Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
    Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
    Wang Y; Wu XJ; Zhao AL; Yuan YH; Chen YT; Jungbluth AA; Gnjatic S; Santiago D; Ritter G; Chen WF; Old LJ; Ji JF
    Cancer Immun; 2004 Nov; 4():11. PubMed ID: 15516106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer.
    Nakada T; Noguchi Y; Satoh S; Ono T; Saika T; Kurashige T; Gnjatic S; Ritter G; Chen YT; Stockert E; Nasu Y; Tsushima T; Kumon H; Old LJ; Nakayama E
    Cancer Immun; 2003 Jul; 3():10. PubMed ID: 12889868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients.
    Mischo A; Wadle A; Wätzig K; Jäger D; Stockert E; Santiago D; Ritter G; Regitz E; Jäger E; Knuth A; Old L; Pfreundschuh M; Renner C
    Cancer Immun; 2003 Jun; 3():5. PubMed ID: 12828452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NY-ESO-1 expression and immunogenicity in esophageal cancer.
    Fujita S; Wada H; Jungbluth AA; Sato S; Nakata T; Noguchi Y; Doki Y; Yasui M; Sugita Y; Yasuda T; Yano M; Ono T; Chen YT; Higashiyama M; Gnjatic S; Old LJ; Nakayama E; Monden M
    Clin Cancer Res; 2004 Oct; 10(19):6551-8. PubMed ID: 15475443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.